8 completed, 1 recruiting, 1 terminated. 6 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Terminated 1 |
| Phase 2 | 6 | Completed 5, Recruiting 1 |
Follow RP6530: new trials by email Literature Review of RP6530 trials Research Report on RP6530
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) Tenalisib - Triple Negative Breast Cancer (TNBC) | Phase 2 | Recruiting | Rhizen Pharmaceuticals SA | 40 | 2024-03-04 | 2025-12-02 |
| Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer Tenalisib 800mg, Tenalisib 1200mg - Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | Completed | Rhizen Pharmaceuticals SA | 40 | 2021-10-13 | 2024-08-13 |
| Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tenalisib - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Completed | Rhizen Pharmaceuticals SA | 21 | 2019-11-28 | 2024-08-13 |
| Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Tenalisib, Romidepsin - T Cell Lymphoma | Phase 1 / Phase 2 | Completed | Rhizen Pharmaceuticals SA | 33 | 2019-03-12 | 2022-10-28 |
| Compassionate Use Study of Tenalisib (RP6530) Tenalisib - Hematological Malignancies | Phase 1 / Phase 2 | Completed | Rhizen Pharmaceuticals SA | 17 | 2018-11-28 | 2024-05-08 |
| Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) Tenalisib, - Non Hodgkin Lymphoma | Phase 2 | Completed | Rhizen Pharmaceuticals SA | 20 | 2018-11-25 | 2021-08-12 |
| Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL Tenalisib, Pembrolizumab - Classical Hodgkin Lymphoma | Phase 1 | Terminated | Rhizen Pharmaceuticals SA | 2 | 2018-07-18 | 2019-12-27 |
| To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers RP6530 - Healthy | Phase 1 | Completed | Rhizen Pharmaceuticals SA | 18 | 2016-02-01 | 2017-11-28 |
| Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma RP6530 - Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous | Phase 1 | Completed | Rhizen Pharmaceuticals SA | 58 | 2015-09-01 | 2020-01-13 |
| Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies RP6530 - Lymphoma, B-Cell, T-Cell Lymphoma | Phase 1 | Completed | Rhizen Pharmaceuticals SA | 35 | 2013-11-01 | 2016-06-24 |
Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell (2) · Lymphoma, T-Cell, Cutaneous (2) · Breast Neoplasms (1) · Fasting (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Triple Negative Breast Neoplasms (1)
Rhizen Pharmaceuticals SA (10)
United States (5) · Georgia (3) · Poland (2) · Australia (1) · Bulgaria (1) · Canada (1) · France (1) · India (1) · Italy (1)
Auris Huen, MD (1) · Carmelo Carlo-stella, MD (1) · Eric Sicard, M.D (1) · Richard Delarue, MD (1)